Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Therapeutics

• Publication date

  2015-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2014.11.015PMID 25626486
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global guideline for type 2 diabetes.

  2014cited by this paper
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379

  2013cited by this paper
• Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients

  2013cited by this paper
• Long-term effectiveness and safety of liraglutide in clinical practice.

  2013cited by this paper
• Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• An overview of the pharmacokinetics, efficacy and safety of liraglutide.

  2012cited by this paper
• Differentiating among incretin therapies: a multiple‐target approach to type 2 diabetes

  2012cited by this paper
• Liraglutide: from clinical trials to clinical practice

  2012cited by this paper
• A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice

  2012cited by this paper
• The design of the liraglutide clinical trial programme

  2012cited by this paper
• Standards of Medical Care in Diabetes—2012

  2011cited by this paper
• Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

  2011cited by this paper
• Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus

  2011cited by this paper
• The role of incretin therapy at different stages of diabetes.

  2011cited by this paper
• Management of type 2 diabetes: NICE guidelines.

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations.

  2008cited by this paper
• beta-cell failure in diabetes and preservation by clinical treatment.

  2007cited by this paper
• The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.

  2005cited by this paper
• Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

  2003cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper

• Predictive factors of response to liraglutide in patients with type 2 diabetes mellitus and metabolic syndrome

  2024cites this paper
• Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors

  2023cites this paper
• Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review

  2023cites this paper
• Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes

  2023cites this paper
• Efficacy and Safety of a Biosimilar Liraglutide (Melitide®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial

  2023cites this paper
• Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study

  2022cites this paper
• Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus

  2022cites this paper
• Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies

  2021cites this paper
• Liraglutide Effects on Glycemic Control and Weight in Patients with Type 2 Diabetes Mellitus: A Real-World, Observational Study and Brief Narrative Review.

  2021cites this paper
• Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients

  2020cites this paper
• Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index

  2019cites this paper
• Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study

  2019cites this paper
• Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area

  2019cites this paper
• Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents

  2019cites this paper
• Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes

  2019cites this paper
• Comparative effectiveness of exenatide once‐weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta‐analysis of observational studies

  2019cites this paper
• Insulin tolerance test predicts non response vs. sustained efficacy of Liraglutide on glycemic control in type 2 diabetes patients: A prospective real-world setting study.

  2018cites this paper
• Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real‐world retrospective study conducted in Spain

  2018cites this paper
• Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study

  2018cites this paper
• Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting

  2018cites this paper
• Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study

  2018cites this paper
• Long-Term Effectiveness of Liraglutide in Association with Patients’ Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study

  2017cites this paper
• Treatment Outcomes and Tolerability Following Initiation of GLP-1 Receptor Agonists Among Type 2 Diabetes Patients in Primary Care Practices in Germany

  2017cites this paper
• Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study

  2017cites this paper
• Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study

  2017cites this paper
• Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.

  2017cites this paper
• Canagliflozin as a replacement therapy for patients with type 2 diabetes not responding to GLP-1 receptor agonists.

  2017cites this paper
• Mi experiencia con liraglutida en pacientes con diabetes mellitus de tipo 2: del ensayo clínico a la práctica clínica

  2017cites this paper
• Mi experiencia sobre el mejor momento para plantear un tratamiento con liraglutida

  2017cites this paper
• Canagliflozin as a replacement therapy for patients with type 2 diabetes not responding to GLP-1 receptor agonists.

  2017cites this paper
• Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting

  2016cites this paper
• Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis

  2016cites this paper
• Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials

  2016cites this paper
• Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta‐analysis of seven phase III trials

  2016cites this paper
• Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis

  2016cites this paper
• A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy

  2016cites this paper
• Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.

  2016cites this paper
• Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review

  2016cites this paper
• RESEARCH ARTICLE OBESITY AND INFLAMMATION.PROBIOTICS OR PHARMACEUTICALS INTERVENTION

  2015cites this paper
• Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case–control study

  2015cites this paper
• Obesity and inflammation: probiotics or pharmaceuticals intervention?

  2015cites this paper
• Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.

  2015cites this paper